Product Information
SEVELAMER HCL 800 MG TABLET is a generic product labeled by Lupin Pharmaceuticals Inc., priced at $0.6952 per EA under NDC 70748017326. Its NADAC has been published 236 times since Mar 30, 2022.
FDA first approved this application on Jun 16, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
800 mg/1
Manufacturer
Lupin Pharmaceuticals Inc.NDC
70748017326
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
SEVELAMER HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA213145FDA Approved
6/16/2021
TE Code
AB
On Market Since
2/25/2022
Pharmacological Classes
Price Statistics
The NADAC for SEVELAMER HCL 800 MG TABLET has been published 236 times since Mar 30, 2022, and over the history we have for it it has declined 84.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6952 per EA |
|---|---|
| All-time high | $4.8175 (Jul 13, 2022) |
| All-time low | $0.6952 (Sep 23, 2026) |
| 52-week high | $1.3660 |
| 52-week low | $0.6952 |
| Median price | $1.5202 |
| Average price | $1.9944 |
| Largest weekly change | -37.7% (May 22, 2024) |
| Weeks tracked | 236 |
| Tracking since | Mar 30, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Sevelamer hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lupin Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Sevelamer hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Phosphate Binder class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SEVELAMER HCL 800 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for SEVELAMER HCL 800 MG TABLET, manufactured by Lupin Pharmaceuticals Inc., is $0.6952 per EA (NDC 70748017326), effective Sep 30, 2026.
How has the price of SEVELAMER HCL 800 MG TABLET changed over time?
Over the history we have for it, the NADAC for SEVELAMER HCL 800 MG TABLET has declined 84.6%. It has been tracked across 236 weekly CMS publications since Mar 30, 2022.
What are the highest and lowest recorded NADAC prices for SEVELAMER HCL 800 MG TABLET?
Since Mar 30, 2022, the NADAC for SEVELAMER HCL 800 MG TABLET has ranged from a low of $0.6952 (Sep 23, 2026) to a high of $4.8175 (Jul 13, 2022), with a median of $1.5202 per EA.
Are there cheaper alternatives to SEVELAMER HCL 800 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of SEVELAMER HCL 800 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures SEVELAMER HCL 800 MG TABLET?
SEVELAMER HCL 800 MG TABLET (NDC 70748017326) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a generic product.